Lanreotide Injection, 120 Mg/0.5 Ml, 0.5 Ml Per Pre-filled Syringe, For Deep Subcutaneous Injection, Rx Only, Manufactured For: Cipla Usa, Inc., 10 Independence Boulevard, Suite 300, Warren, Nj 07059.
Recall Summary Cipla USA is recalling Lanreotide Injection 120 mg pre-filled syringes nationwide because the medication contains particulate matter (small particles) in the liquid. This is a serious recall affecting all U.S. states and Washington, D.C. Patients who have received this injectable drug for treatment should contact their healthcare provider.
- Recalling firm
- Cipla USA, Inc.
- Product
- Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-870-67
- Reason
- Presence of Particulate Matter.
- Classification
- Class I
- Category
- drug recall
- Country
- United States
- Agency
- U.S. Food and Drug Administration
- Recall date
- 2026-01-02
- Status
- Ongoing
- Areas affected
- AL, AK, AZ, AR, CA, CO, CT, DE, FL, GA, HI, ID, ...
- Distribution
- Nationwide in the USA
Official recall notice from U.S. Food and Drug Administration
Recall details on Nibble Recalls: https://trynibble.app/recalls/18270864-545e-4487-a8d5-8103635de8ba